Log Out
 

The neuropeptide calcitonin gene-related peptide (CGRP) plays a significant role in chronic neuropathic pain, and the therapeutic benefits of anti-CGRP monoclonal antibodies (mAbs) in migraine treatment are well established. However, CGRP is not only expressed in the central nervous system, but also in nearly all human organs.1 In a presentation at the 13th annual congress of the European Headache Federation, Prof. David W. Dodick (Mayo Clinic, USA) provided a brief overview of recent studies on the use of anti-CGRP mAbs in non-migraine pain conditions.

Thus far, clinical trial results have not demonstrated a therapeutic benefit of anti-CGRP mAbs in cluster headache. Prof. Dodick questioned whether patient population and outcome measure selection could be improved to properly answer the research question, and emphasised that additional studies of anti-CGRP mAbs in cluster headache should be conducted.